Key Takeaways Most trials do not measure meaningful change until at least one month, with pain relief typically building gradually through 3 to 6 months. By 12 months, trial data show improvements in both pain and function, with dose and cell source affecting how strong and how long-lasting that benefit
Key Takeaways A 2024 network meta-analysis of 48 studies ranked PRP highest for knee osteoarthritis pain and function, followed by a bone marrow cell-based option, then hyaluronic acid (HA). The cell-based option’s ranking rests on far fewer studies (2.5% of the pooled evidence) than HA’s ranking (nearly 41%), so that
Key Takeaways Umbilical cord MSCs for stroke are being studied as a possible add-on to standard rehabilitation, not a replacement for it. A 2025 randomized trial in 32 patients found IV delivery led to significant improvements at 6 months, with both IV and intrathecal groups improving by 12 months. A
Key Takeaways Stem cells for disc degeneration can be delivered in two ways: intradiscal injection straight into the disc, or IV infusion through a vein. A 2014 mouse study found intradiscal injection preserved disc height better, while IV delivery still boosted some tissue-repair markers without that structural effect. Cyrona Cell
Key Takeaways Chronic, low-grade inflammation and insulin resistance drive each other in a two-way loop that starts largely in visceral fat. Mesenchymal stem cells are being studied for their ability to calm this inflammation and support insulin sensitivity, not to replace diet, exercise, or medication. A 2022 randomized trial found
Key Takeaways A 2026 study in Scientific Reports followed 49 patients with steroid-resistant GvHD treated with Wharton’s jelly MSCs at four hospitals in Spain. At day 28, 71.4% of patients responded to treatment. One-year survival reached 55.1%. Batches that scored above 70% on a potency test produced far better outcomes,
Key Takeaways Hypoxic brain injury is caused by reduced oxygen; anoxic brain injury by a complete stop. Both damage the same brain tissue but anoxic injuries tend to be more severe. Stem cell therapy supports recovery in both by releasing neurotrophic factors, reducing inflammation, and providing an environment for surviving
Key Takeaways Researchers at MUSC report that engineered mesenchymal stem cells reversed new-onset type 1 diabetes in mice, pointing to the disease’s immune response rather than just its symptoms. The cells were modified to overexpress a protein called alpha-1 antitrypsin, which calmed the autoimmune attack and protected insulin producing beta
Key Takeaways Stem cell therapy can slow cellular aging by targeting the immune system dysfunction and chronic inflammation that drive the aging process at the cellular level. Growth factors released by mesenchymal stem cells (MSCs) support boosting collagen, repairing damaged tissue, and improving skin quality from within. Findings show improvements
Key Takeaways The realistic goals of stem cell therapy for MS are slowing disease activity, reducing fatigue, and improving mobility, not reversing all past damage. Mesenchymal stem cells (MSCs) calm the immune system and protect nerve fibers. Hematopoietic stem cell transplant (HSCT) goes further, aiming to reset the immune system
